agm and resolution, page-11

I disagree. Doing the same thing over and over and expecting a different outcome isnt my idea of good management. The NASDAQ is key to extract value for a biotech with biotas progression in trials. Not so for phase I but with phase II and phase III the NASDAQ does give you a fair trot. Not going to harp on, but this is the time to do it. Prior late stage trial results.

The Aussie market appreciates earnings, see COH and CSL. The Aussie market doesn't value phase 2 and 3 pipeline products appropriately IMHO.

It is an exciting time for biota. It's time to step up and play with the big boys.